5- (phenylisoxazolylethoxy) -triazol3 - yl substituted pyridine compounds for the treatment of neurological, psychiatric or pain disorders

Details for Australian Patent Application No. 2006297462 (hide)

Owner AstraZeneca AB

Inventors Ericsson, Caroline; Edwards, Louise; Minidis, Alexander; Profir, Veronica; Xin, Tao; Wensbo, David; Arora, Jalaj; Bergstrom, Per-Olov; Isaac, Methvin; Slassi, Abdelmalik

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2006297462

PCT Pub. Number WO2007/040982

Priority 60/721,527 29.09.05 US

Filing date 20 September 2006

Wipo publication date 12 April 2007

International Classifications

C07D 413/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

A61K 31/00 (2006.01)

A61P 1/04 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

Event Publications

10 April 2008 PCT application entered the National Phase

  PCT publication WO2007/040982 Priority application(s): WO2007/040982

12 April 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006297467-Integrated engine control and cooling system for diesel engines

2006297452-Acylated piperidine derivatives as melanocortin-4 receptor agonists